No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Clin Infect Dis. 2016 Nov 1;63(9):1202-1204. doi: 10.1093/cid/ciw507. Epub 2016 Aug 2.

Abstract

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

Keywords: ALT flare; HBV reactivation; HCV/HBV coinfection.

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Coinfection
  • Drug Therapy, Combination
  • Female
  • Fluorenes / therapeutic use*
  • Hepatitis B / complications
  • Hepatitis B / virology*
  • Hepatitis B virus / drug effects*
  • Hepatitis C / complications
  • Hepatitis C / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Sofosbuvir / therapeutic use*
  • Virus Activation / drug effects*

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • ledipasvir
  • Sofosbuvir